Annual Accounts Receivable:
$4.36B+$309.48M(+7.65%)Summary
- As of today, TAK annual accounts receivable is $4.36 billion, with the most recent change of +$309.48 million (+7.65%) on March 31, 2025.
- During the last 3 years, TAK annual accounts receivable has fallen by -$731.56 million (-14.38%).
- TAK annual accounts receivable is now -31.96% below its all-time high of $6.40 billion, reached on March 31, 2021.
Performance
TAK Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly Accounts Receivable:
$4.67B+$56.88M(+1.23%)Summary
- As of today, TAK quarterly accounts receivable is $4.67 billion, with the most recent change of +$56.88 million (+1.23%) on September 1, 2025.
- Over the past year, TAK quarterly accounts receivable has dropped by -$232.41 million (-4.75%).
- TAK quarterly accounts receivable is now -39.15% below its all-time high of $7.67 billion, reached on December 31, 2020.
Performance
TAK Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
TAK Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1Y1 Year | +7.7% | -4.8% |
| 3Y3 Years | -14.4% | -11.1% |
| 5Y5 Years | -29.9% | -34.7% |
TAK Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | |
|---|---|---|---|---|---|
| 3Y | 3-Year | -14.4% | +7.7% | -15.0% | +15.3% |
| 5Y | 5-Year | -32.0% | +7.7% | -39.1% | +15.3% |
| All-Time | All-Time | -32.0% | +154.9% | -39.1% | +45.8% |
TAK Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2025 | - | $4.67B(+1.2%) |
| Jun 2025 | - | $4.61B(+5.8%) |
| Mar 2025 | $4.36B(+7.6%) | $4.36B(-3.8%) |
| Dec 2024 | - | $4.53B(-7.6%) |
| Sep 2024 | - | $4.90B(+4.3%) |
| Jun 2024 | - | $4.70B(+16.1%) |
| Mar 2024 | $4.05B(-6.4%) | $4.05B(-20.3%) |
| Dec 2023 | - | $5.08B(+0.4%) |
| Sep 2023 | - | $5.06B(-7.7%) |
| Jun 2023 | - | $5.49B(+26.9%) |
| Mar 2023 | $4.32B(-15.0%) | $4.32B(-19.3%) |
| Dec 2022 | - | $5.36B(+2.1%) |
| Sep 2022 | - | $5.25B(-6.4%) |
| Jun 2022 | - | $5.61B(+10.3%) |
| Mar 2022 | $5.09B(-20.5%) | $5.09B(-18.1%) |
| Dec 2021 | - | $6.21B(-17.8%) |
| Sep 2021 | - | $7.56B(+1.4%) |
| Jun 2021 | - | $7.45B(+16.4%) |
| Mar 2021 | $6.40B(+3.1%) | $6.40B(-16.5%) |
| Dec 2020 | - | $7.67B(+7.3%) |
| Sep 2020 | - | $7.14B(-1.8%) |
| Jun 2020 | - | $7.27B(+17.1%) |
| Mar 2020 | $6.21B(+4.6%) | $6.21B(-17.7%) |
| Dec 2019 | - | $7.55B(+4.7%) |
| Sep 2019 | - | $7.21B(+2.2%) |
| Jun 2019 | - | $7.06B(+18.7%) |
| Mar 2019 | $5.94B(+75.1%) | $5.94B(+28.0%) |
| Dec 2018 | - | $4.64B(+14.3%) |
| Sep 2018 | - | $4.06B(-0.2%) |
| Jun 2018 | - | $4.07B(+19.9%) |
| Mar 2018 | $3.39B(+6.1%) | $3.39B(-25.3%) |
| Dec 2017 | - | $4.54B(+9.6%) |
| Sep 2017 | - | $4.14B(+4.7%) |
| Jun 2017 | - | $3.96B(+23.8%) |
| Mar 2017 | $3.20B(-4.5%) | $3.20B(-23.9%) |
| Dec 2016 | - | $4.20B(-2.5%) |
| Sep 2016 | - | $4.31B(+3.6%) |
| Jun 2016 | - | $4.16B(+24.2%) |
| Mar 2016 | $3.35B | $3.35B(-16.7%) |
| Dec 2015 | - | $4.02B(+2.1%) |
| Sep 2015 | - | $3.94B(+4.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2015 | - | $3.77B(+12.8%) |
| Mar 2015 | $3.34B(-8.4%) | $3.34B(-18.1%) |
| Dec 2014 | - | $4.08B(-1.7%) |
| Sep 2014 | - | $4.15B(-1.1%) |
| Jun 2014 | - | $4.20B(+13.6%) |
| Mar 2014 | $3.65B(+0.2%) | $3.69B(-8.3%) |
| Dec 2013 | - | $4.03B(+3.5%) |
| Sep 2013 | - | $3.89B(+6.4%) |
| Jun 2013 | - | $3.66B(+0.5%) |
| Mar 2013 | $3.64B(-12.3%) | $3.64B(-16.5%) |
| Dec 2012 | - | $4.36B(+2.5%) |
| Sep 2012 | - | $4.26B(+1.5%) |
| Jun 2012 | - | $4.19B(+0.9%) |
| Mar 2012 | $4.15B(+17.5%) | $4.15B(-14.3%) |
| Dec 2011 | - | $4.85B(+7.2%) |
| Sep 2011 | - | $4.52B(+22.2%) |
| Jun 2011 | - | $3.70B(+4.7%) |
| Mar 2011 | $3.54B(+18.1%) | $3.54B(-8.7%) |
| Dec 2010 | - | $3.87B(+9.7%) |
| Sep 2010 | - | $3.53B(+7.6%) |
| Jun 2010 | - | $3.28B(-13.0%) |
| Mar 2010 | $2.99B(-1.9%) | - |
| Mar 2009 | $3.05B(+22.8%) | - |
| Dec 2008 | - | $3.77B |
| Mar 2008 | $2.48B(+12.2%) | - |
| Mar 2007 | $2.21B(+10.5%) | - |
| Mar 2006 | $2.00B(-4.9%) | - |
| Mar 2005 | $2.11B(+4.5%) | - |
| Mar 2004 | $2.02B(+18.0%) | - |
| Mar 2003 | $1.71B(-3.6%) | - |
| Mar 2002 | $1.77B(-12.6%) | - |
| Mar 2001 | $2.03B(-10.9%) | - |
| Mar 2000 | $2.28B(+19.5%) | - |
| Mar 1999 | $1.91B(+10.3%) | - |
| Mar 1998 | $1.73B(-14.0%) | - |
| Mar 1997 | $2.01B(-17.1%) | - |
| Mar 1996 | $2.42B(-13.7%) | - |
| Mar 1995 | $2.81B(+25.4%) | - |
| Mar 1994 | $2.24B(+22.6%) | - |
| Mar 1993 | $1.83B(-1.7%) | - |
| Mar 1992 | $1.86B | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual accounts receivable?
- What is the all-time high annual accounts receivable for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual accounts receivable year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly accounts receivable?
- What is the all-time high quarterly accounts receivable for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly accounts receivable year-on-year change?
What is Takeda Pharmaceutical Company Limited annual accounts receivable?
The current annual accounts receivable of TAK is $4.36B
What is the all-time high annual accounts receivable for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual accounts receivable is $6.40B
What is Takeda Pharmaceutical Company Limited annual accounts receivable year-on-year change?
Over the past year, TAK annual accounts receivable has changed by +$309.48M (+7.65%)
What is Takeda Pharmaceutical Company Limited quarterly accounts receivable?
The current quarterly accounts receivable of TAK is $4.67B
What is the all-time high quarterly accounts receivable for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly accounts receivable is $7.67B
What is Takeda Pharmaceutical Company Limited quarterly accounts receivable year-on-year change?
Over the past year, TAK quarterly accounts receivable has changed by -$232.41M (-4.75%)